ArticleFrontiers in immunology2026
CPEB1 drives ferroptosis-neuroinflammation crosstalk in temporal lobe epilepsy via the SIRT1-NRF2 acetylation axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Temporal lobe epilepsy (TLE) is a common neurological disorder frequently resistant to pharmacological treatment, yet its molecular mechanisms remain incompletely understood. Cytoplasmic polyadenylation element-binding protein 1 (CPEB1) is a post-transcriptional regulator implicated in neuronal stress responses; however, its role in epilepsy and redox-inflammatory signaling remains unclear. Methods: An integrative multi-omics strategy combining single-cell transcriptomics, bulk RNA sequencing, and bioinformatics analyses was employed, followed by validation in human epileptic hippocampal tissues, kainic acid (KA)- and pentylenetetrazol (PTZ)-induced mouse models, as well as Results: CPEB1 was markedly upregulated in neurons from both TLE patients and experimental models. Neuronal overexpression of CPEB1 increased seizure susceptibility, exacerbated neuronal loss, and promoted oxidative stress, proinflammatory cytokine release, and ferroptosis, whereas CPEB1 knockdown exerted robust neuroprotective effects. Mechanistically, CPEB1 suppressed SIRT1 activity, leading to enhanced acetylation-dependent destabilization of NRF2, impaired downstream SLC7A11/GPX4 antioxidant signaling, and excessive reactive oxygen species (ROS) accumulation, ultimately triggering ferroptotic neuronal death. Importantly, pharmacological inhibition of SIRT1 or NRF2 abolished the neuroprotective effects of CPEB1 knockdown, confirming the critical role of the CPEB1-SIRT1-NRF2 acetylation axis in TLE pathogenesis. Conclusion: CPEB1 aggravates neuronal injury in TLE by driving ferroptosis-neuroinflammation crosstalk through suppression of the SIRT1-NRF2 acetylation axis. Targeting this pathway may provide a promising therapeutic strategy for drug-resistant epilepsy and related neurodegenerative disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.